Point72 Asset Management's 6.2% Stake in Palisade Bio, Inc.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G with the SEC, disclosing a 6.2% beneficial ownership in Palisade Bio, Inc. The filing, dated October 6, 2025, indicates that Point72 Asset Management maintains investment and voting power over the shares held by Point72 Associates, LLC, an investment fund it manages. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. The filing is made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934, and the parties have entered into a Joint Filing Agreement to file this statement jointly. The shares are held for investment purposes and not with the intent to influence control of Palisade Bio, Inc.